Werkgroep Cardiologische centra Nederland

CLEAR 1002-043 (Follow-up)

A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant
Medicine
bepedoic acid
Population
ASCVD
Phase
III
Starting year
2016
More information
Clinicaltrials.gov

Director of Study

dr. E. Ronner (Cardioloog)
Delft, Reinier de Graaf Gasthuis